Drug intelligence / Profile preview

[225Ac]Ac-HTK03170

Development stage
Preclinical
Lead developer
BC Cancer
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Peptides
Administration
Intravenous
01

Overview

[225Ac]Ac-HTK03170 is a preclinical-stage, prostate-specific membrane antigen (PSMA)-targeting radioligand therapy (RLT) labeled with the alpha-emitting radionuclide Actinium-225 ([225Ac]). Developed by BC Cancer and the University of British Columbia, the compound is designed for targeted alpha therapy (TAT) of advanced prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC). It consists of a PSMA-targeting small-molecule ligand conjugated to a DOTA chelator and incorporates a 4-(4-methoxyphenyl)butyric acid moiety as an albumin binder. This albumin-binding moiety extends the blood circulation half-life, enhancing tumor accumulation and therapeutic efficacy while minimizing off-target toxicity in salivary glands and kidneys. In preclinical models, [225Ac]Ac-HTK03170 has demonstrated high tumor uptake, favorable pharmacokinetics, and significant tumor regression.

Other names
225Ac-HTK03170Actinium-225 HTK03170Actinium225 HTK03170Actinium 225 HTK03170actinium (225Ac) HTK03170
02

Identity

Drug type
Radiopharmaceuticals
Originator
BC Cancer
Modality
PeptidesAntibody-Based TherapeuticsAntibody-Radionuclide ConjugatesAlpha Emitters
Synonyms and codes
HTK03170
03

Pharmacology

Route
Intravenous
04

Development

IndicationHighest phaseStatus
metastatic castration-resistant prostate cancer (mCRPC)PreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • BC CancerOriginator · Lead developer
07

Patents & exclusivity

Patents
1

Patent families, expiry dates and exclusivities are in the full profile.

08

Competitive landscape

Drugs on the same target
195
Drugs in the lead indication
614

Lead indication: metastatic castration-resistant prostate cancer (mCRPC)

Most advanced in the lead indication

  1. lutetium-177Approved
  2. lutetium-177 PSMAApproved
  3. lutetium Lu 177 PSMA radioligand therapyApproved
  4. 18F-PSMA-11Approved
  5. abirateroneApproved

Beyond the preview

Go deeper on [225Ac]Ac-HTK03170.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [225Ac]Ac-HTK03170.

Work on [225Ac]Ac-HTK03170? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call